In the latest trading session, 2.37 million RAPT Therapeutics Inc (NASDAQ:RAPT) shares changed hands as the company’s beta touched 0.01. With the company’s most recent per share price at $1.63 changed hands at -$0.11 or -6.03% at last look, the market valuation stands at $57.16M. RAPT’s current price is a discount, trading about -1577.91% off its 52-week high of $27.35. The share price had its 52-week low at $0.79, which suggests the last value was 51.53% up since then. When we look at RAPT Therapeutics Inc’s average trading volume, we note the 10-day average is 14.42 million shares, with the 3-month average coming to 2.76 million.
Analysts gave the RAPT Therapeutics Inc (RAPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended RAPT as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RAPT Therapeutics Inc (NASDAQ:RAPT) trade information
Instantly RAPT was in red as seen in intraday trades today. With action 94.39%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -93.42%, with the 5-day performance at 94.39% in the green. However, in the 30-day time frame, RAPT Therapeutics Inc (NASDAQ:RAPT) is 51.39% up. Looking at the short shares, we see there were 1.37 million shares sold at short interest cover period of 1.32 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 18.5% from its recent market value. According to analyst projections, RAPT’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -22.7% plunge from its current level, while the stock would need to soar -22.7% for it to hit the projected low.
RAPT Therapeutics Inc (RAPT) estimates and forecasts
Data shows that the RAPT Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -46.39% over the past 6 months, a 6.23% in annual growth rate that is considerably lower than the industry average of 16.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.39%. The 2024 estimates are for RAPT Therapeutics Inc earnings to increase by 19.56%.
RAPT Dividends
RAPT Therapeutics Inc is expected to release its next quarterly earnings report in January.
RAPT Therapeutics Inc (NASDAQ:RAPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.84% of RAPT Therapeutics Inc shares while 86.62% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.24%. There are 86.62% institutions holding the RAPT Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 13.5546% of the shares, roughly 5.24 million RAPT shares worth $15.97 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.0472% or 3.11 million shares worth $9.48 million as of 2024-06-30.
